Novavax Archives | Be Korea-savvy
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

GAITHERSBURG, Md., Oct. 27 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. The Company [...]

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

GAITHERSBURG, Md., Oct. 20 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Company’s COVID-19 vaccine, at the 2020 World Vaccine Congress Europe. The Congress takes place virtually October 19 [...]

Novavax Appoints Leadership Team to Advance NanoFlu Through Regulatory Licensure

Novavax Appoints Leadership Team to Advance NanoFlu Through Regulatory Licensure

GAITHERSBURG, Md., Oct. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created [...]

Novavax to Participate in Upcoming Conferences

Novavax to Participate in Upcoming Conferences

GAITHERSBURG, Md., Oct. 5 (Korea Bizwire) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in four upcoming investor and industry conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, is expected to be discussed in each conference. Maryland Life Sciences Bio Innovation Conference Date: [...]

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020

GAITHERSBURG, Md., Sept. 28 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The presentations are part of the 2020 [...]

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

GAITHERSBURG, Md., Sept. 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United [...]

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

GAITHERSBURG, Md., Sept. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this [...]

Novavax to Participate in Upcoming Investor Conferences

Novavax to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 10 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373. Conference details are as follows: Citi 15th Annual BioPharma Virtual Conference Date: [...]

Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine

Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine

GAITHERSBURG, Md., Sept. 2 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX‑CoV2373, its COVID‑19 vaccine candidate adjuvanted with Matrix‑M™, in healthy adults 18-59 [...]

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

GAITHERSBURG, Md., Aug. 31 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine. “We are pleased to work with [...]